论文信息 - Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial. - 字舞流文

Five year letrozole versus placebo in BRCA1/2 germline mutations carriers: Final results of LIBER, a double-blind randomized phase III breast cancer prevention trial.

J. Lemonnier | P. Pujol | J. Fricker | S. Delaloge | C. Lasset | P. Berthet | C. Dugast | L. Venat-Bouvet | H. Dreyfus | J. Chiésa | P. Gesta | A. Lortholary | I. Tennevet | P. This | T. Nguyen | L. Roca | A. Mailliez | V. Galibert | Capucine Delnatte | Chabbert-Buffet Nathalie